Understand the source comparison
Comparison: GLP-1 Agonists and Growth Hormone Secretagogues for Wedding Prep
Tirzepatide Dual GLP-1/GIP receptor agonist. Slows gastric emptying, enhances insulin sensitivity Once weekly subcutaneous Superior appetite suppression (20.9% mean body weight reduction in SURMOUNT-1 trial at 72 weeks) Nausea 30–40% during titration; resolves
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide
- Dual GLP-1/GIP receptor agonist. Slows gastric emptying, enhances insulin sensitivity
- Once weekly subcutaneous
- Superior appetite suppression (20.9% mean body weight reduction in SURMOUNT-1 trial at 72 weeks)
- Nausea 30–40% during titration; resolves by week 8 in most cases
- Best single-agent option for fat loss with minimal muscle loss. Superior to semaglutide for body recomposition timelines
- Semaglutide
- GLP-1 receptor agonist. Delays gastric emptying, reduces appetite signaling centrally
- Proven long-term safety profile; 14.9% mean weight reduction in STEP-1 trial at 68 weeks
- Nausea 25–35% during titration; lower incidence than tirzepatide but slower fat loss
- Reliable choice for clients prioritizing tolerability over maximum velocity. Still produces meaningful results in 12-week window
- CJC-1295/Ipamorelin
- Growth hormone secretagogue. Stimulates pituitary GH release in pulsatile fashion
- Nightly subcutaneous before bed
- Preserves lean mass during deficit; enhances lipolysis without hunger stimulation
- Injection site irritation; transient flushing in 10–15% of users
- Ideal pairing with GLP-1 agents. Addresses muscle retention without appetite interference
- MK-677 (Ibutamoren)
- Ghrelin mimetic. Produces sustained 8–12 hour GH elevation
- Once daily oral (morning or night)
- Oral administration; sustained GH elevation vs pulsatile; improves sleep quality
- Increased appetite (controlled by concurrent GLP-1 use); transient water retention first 2 weeks
- Preferred for clients averse to injections or seeking sleep/recovery benefits. Hunger effect is paradoxically nullified by GLP-1 co-administration